Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18510216 | 1.00 | POLB (0.40) | POLBALOX5CHRM2CHRM1TSHR | |
| SCHEMBL6467731 | 0.79 | — | — | |
| SCHEMBL13779182 | 0.78 | ALDH1A1 (0.39) | POLBTSHRKMT2A | |
| SCHEMBL25008447 | 0.75 | CHRM1 (0.37) | CHRM1 | |
| SCHEMBL12192813 | 0.75 | ELANE (0.32) | — | |
| SCHEMBL12215928 | 0.75 | CHRM2 (0.41) | CHRM2CHRM1TSHRCHRM4CHRM3 | |
| SCHEMBL13158425 | 0.72 | PRKCA (0.36) | TSHR | |
| SCHEMBL8149193 | 0.72 | POLB (0.34) | POLBALOX5CHRM2CHRM1TSHR | |
| SCHEMBL2130385 | 0.72 | ALDH1A1 (0.46) | POLBMEN1CYP2D6KMT2AALOX15 | |
| SCHEMBL2130382 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310486-A1 | CONJUGATED OLIGONUCLEOTIDE COMPOUNDS, METHODS OF MAKING AND USES THEREOF | E-THERAPEUTICS PLC (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230287217-A1 | Zwitterionic Cell-Permeant and Water-Soluble Rhodamine Dyes for Quantitative Imaging Applications | OREGON HEALTH & SCIENCE UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230287217-A1 | Zwitterionic Cell-Permeant and Water-Soluble Rhodamine Dyes for Quantitative Imaging Applications | OREGON HEALTH & SCIENCE UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| EP-3706742-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| US-10947234-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10875895-B2 | Antibacterial cell-penetrating peptides | PURDUE RESEARCH FOUNDATION (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200361931-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-11-19 | — | — | US | disclosed |
| EP-3706742-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200172579-A1 | NOVEL ANTIBACTERIAL CELL-PENETRATING PEPTIDES | PURDUE RESEARCH FOUNDATION (US) | 2020-06-04 | — | — | US | disclosed |
| US-10041950-B2 | Signaling conjugates and methods of use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | VANDERBILT UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-8372868-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2013-02-12 | — | — | US | disclosed |
| US-8188116-B2 | Ligand/drug conjugates; near infrared radiation imaging; peripheral benzodiazepine receptor imaging; drug delivery; drug targets; cancer, metastasis | VANDERBILT UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110269713-A1 | BRYOSTATIN ANALOGUES AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110165084-A1 | VIVO DETECTION OF PHOSPHOLIPASE ACTIVATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-07-07 | — | — | US | disclosed |
| US-20100278739-A1 | TARGETED, NIR IMAGING AGENTS FOR THERAPY EFFICACY MONITORING, DEEP TISSUE DISEASE DEMARCATION AND DEEP TISSUE IMAGING | VANDERBILT UNIVERSITY | 2010-11-04 | — | — | US | disclosed |
| US-7754884-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2010-07-13 | — | — | US | disclosed |
| US-7507395-B2 | Methods of using fluorescent pH indicators for intracellular assays | MDS ANALYTICAL TECHNOLOGIES (US) INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507395-B2 | Methods of using fluorescent pH indicators for intracellular assays | MDS ANALYTICAL TECHNOLOGIES (US) INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | US GOVERNMENT - SECRETARY FOR THE ARMY | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165084-A1 | VIVO DETECTION OF PHOSPHOLIPASE ACTIVATION | PLA2G4A, PLA2G4C, PLA2G4B | POLB 1719/4885ALOX5 87/4885CHRM2 3536/4885 |
| US-20200361931-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | POLB 3111/4885ALOX5 3649/4885CHRM2 4042/4885 |
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | TSPO, MKI67, CNR1 | POLB 1622/4885ALOX5 2112/4885CHRM2 597/4885 |
| US-10875895-B2 | Antibacterial cell-penetrating peptides | VIP, NRDC, NGLY1 | POLB 2308/4885ALOX5 4396/4885CHRM2 4835/4885 |
| US-20110269713-A1 | BRYOSTATIN ANALOGUES AND METHODS OF MAKING AND USING THEREOF | PRKAR2B, PRKAR2A, PRKCH | POLB 4351/4885ALOX5 2041/4885CHRM2 2999/4885 |
| US-20200172579-A1 | NOVEL ANTIBACTERIAL CELL-PENETRATING PEPTIDES | VIP, NRDC, NGLY1 | POLB 2550/4885ALOX5 4484/4885CHRM2 4811/4885 |
| US-20100278739-A1 | TARGETED, NIR IMAGING AGENTS FOR THERAPY EFFICACY MONITORING, DEEP TISSUE DISEASE DEMARCATION AND DEEP TISSUE IMAGING | TSPO, MKI67, GABRA4 | POLB 1768/4885ALOX5 2156/4885CHRM2 330/4885 |
| US-20230310486-A1 | CONJUGATED OLIGONUCLEOTIDE COMPOUNDS, METHODS OF MAKING AND USES THEREOF | DCLRE1B, POLRMT, POLI | POLB 11/4885ALOX5 615/4885CHRM2 4769/4885 |
| US-10947234-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | POLB 3111/4885ALOX5 3649/4885CHRM2 4042/4885 |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | TSPO, MKI67, GABRA4 | POLB 1768/4885ALOX5 2156/4885CHRM2 330/4885 |
| US-20230287217-A1 | Zwitterionic Cell-Permeant and Water-Soluble Rhodamine Dyes for Quantitative Imaging Applications | SLC1A5, SLCO1B1, SLCO2B1 | POLB 4012/4885ALOX5 2241/4885CHRM2 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.